Emergex’s dengue vaccine candidate receives regulatory approval for its first phase clinical trial

UK – A company tackling major global infectious disease threats through the development of 100% synthetic ‘set point’ vaccines, Emergex Vaccines Holding has received regulatory approval for its phase 1 clinical trials of its Dengue Vaccine, pepGNP-Dengue. With approval from Swiss regulatory agencies, Emergex is set to enroll its first participants for the trial phase. The naNO-DENGUE phase 1 trials will evaluate Emergex’s novel T-Cell priming vaccine, which has been designed to deliver broad and long-lasting immunity by priming the body’s T-Cell response to provide rapid clearance of infected cells…

Read More